Radiation Oncology Prior Authorization

For radiation oncology leaders, an authorization approval can feel like a milestone. It is not the end of the reimbursement risk. The approval reflects a particular clinical plan, at a particular moment, under a particular payer policy. Radiation therapy, however, is a course of care that can change after simulation, during planning, and between fractions. The discipline that matters is keeping the authorization aligned with the treatment actually delivered.

This is more than an administrative issue. In ASTRO’s 2024 survey of more than 750 radiation oncologists, 92% reported that prior authorization causes treatment delays, and 94% said it worsens staff burnout. Those results describe physician experiences rather than a universal denial rate, but they underscore the clinical and operational stakes when approvals do not keep pace with care.

The most common authorization breakdown: approval and treatment diverge🔗

A payer may review the treatment site, modality, planned fractions, technique, medical necessity, and supporting records. Meanwhile, the oncologist and treatment team may refine the plan after simulation, change the fractionation schedule, add active motion management, or replan because of changes in anatomy or tumor response. Each clinically appropriate change raises a separate operational question: Does the existing authorization still match what will be provided and billed?

Consider a patient approved for a planned treatment course whose plan changes after new imaging. The clinical team updates the plan, but the authorization work queue still shows the original details. The mismatch may not be discovered until claim submission. The avoidable work is not simply the appeal: it includes retrieving documentation, reconstructing the sequence of decisions, and determining whether a modification should have been requested earlier. Authorization governance has to follow the treatment course rather than stop at initial approval.

Payer requirements change with codes, techniques, and sites of service🔗

Radiation oncology presents a particularly demanding mix of clinical specificity and payer variation. Commercial and Medicare Advantage plans may use utilization-management vendors, proprietary clinical guidelines, and different documentation or notification processes. A code accepted by one payer may require a distinct authorization pathway for another. Hospital-based, freestanding, and hybrid programs may also encounter different claims and billing structures. Teams should not assume that a completed portal transaction establishes coverage for every associated service.

The 2026 treatment-delivery code revisions add a concrete example. Under the revised framework, the delivery codes 77402, 77407, and 77412 describe levels of complexity; level selection is not simply a stand-in for 3D versus IMRT. ASTRO reported early authorization denials involving 77412, including payer interpretations of multiple isocenters and documentation for active motion management. A strong workflow checks both the current coding structure and the payer’s current clinical policy before a case is submitted.

Documentation must explain why the treatment is appropriate🔗

A request can be clinically justified and still fall short of what a reviewer needs. In early 2026 ASTRO highlighted issues where a brief notation such as “DIBH” did not fully explain active motion management. Depending on payer policy, the record may need to describe the reason motion management is necessary, the monitoring or gating system, how it operates during delivery, and how the treatment team acts on the information. This is not an invitation to document more for its own sake. It is an argument for documentation that connects the clinical decision to the service being requested.

Peer-to-peer review creates another friction point. In a busy department, arranging a conversation among the treating radiation oncologist, payer reviewer, and authorization staff can delay start dates. The team should prepare a concise, consistent case summary before escalation: diagnosis and stage as relevant, prior treatment, proposed technique, clinical rationale, number of fractions, supporting notes, and the exact guideline at issue. A prepared appeal packet supports a clinically grounded conversation rather than forcing clinicians to reconstruct the case at the last minute.

When treatment changes, the authorization workflow should change with it🔗

The most effective control is a clear trigger, not a vague request for “better communication.” Define events that require an authorization check: a change in planned technique or fractions; treatment-site or laterality corrections; replanning or addition of services; significant schedule interruption where authorization dates are affected; a switch in payer or care setting; and any payer-specific requirement identified by the team. For each event, specify who notifies authorization, who determines whether an update is required, and who confirms the decision in the oncology information system or shared work queue.

A practical model pairs a pre-treatment authorization reconciliation with ongoing exception review. Before the first fraction, compare the approved service and date window with the final plan. During treatment, route plan changes into a tracked queue rather than informal email alone. Before charges release, confirm that the services and dates are within the applicable authorization or that the correct documented exception applies. Urgent clinical treatment decisions remain clinical decisions; the escalation procedure should support timely care, not become a barrier to it.

Build a performance view that helps leaders intervene🔗

A simple authorization dashboard is more useful than a count of completed requests. Separate initial approvals from reauthorizations, partial approvals, peer-to-peers, denials, appeals, and starts delayed by authorization. Track average turnaround by payer and technique, days from decision to first treatment, modifications required after a plan change, and denials with authorization as the true root cause. Trends can reveal an upstream failure—for example, one payer whose approvals routinely lag after replanning—before the problem appears as a month-end A/R spike.

At Medusind, our radiation oncology approach emphasizes specialty-informed workflows, coding oversight, and clear accountability across the treatment course. The goal is not merely to secure more approvals. It is to help practices keep the clinical plan, the approval, the delivered care, and the claim aligned—supporting timely care and more defensible reimbursement.

Explore how treatment-course alignment can strengthen your revenue cycle.

Sources: ASTRO, “New ASTRO survey finds that prior authorization delays lead to serious harm for people with cancer” (Dec. 4, 2024); ASTRO, “Early 2026 Prior Authorization denial trends” (Jan. 14, 2026); ASTRO, “ASTRO continues prior authorization advocacy” (Jan. 21, 2026); UnitedHealthcare, “New simplified radiation therapy prior authorizations” (2026).